Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neratinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and paclitaxel, a taxane chemotherapy agent. This combination is primarily used in the treatment of HER2-positive breast cancer, including metastatic disease. The dual mechanism targets both HER2 signaling pathways and microtubule function to inhibit cancer cell growth and proliferation.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on neratinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neratinib + paclitaxel.